

Medivir AB - “Simeprevir in the HCV Race - Value Un-Appreciated”

<https://marketpublishers.com/r/MC0A4084F7EEN.html>

Date: August 2012

Pages: 4

Price: US\$ 140.00 (Single User License)

ID: MC0A4084F7EEN

Abstracts

Medivir's (MVIR) future depends on the successful launch and sales of Simeprevir (TMC435, once daily Protease Inhibitor, PI, PhIII, HCV, partnered with Tibotec/JNJ). Simeprevir is a single pill/qd vs. Incivek 2pills/tid and Merck's Victrelis 4pills/tid and we are positive on the approval by YE13/1H14. Setbacks in the IFN-free oral option pipeline esp. discontinuation of Bristol Myers' (BMJ) BMS-986094 (Nucleotide Polymerase Inhibitor, PhII) could change the timelines and dynamics of these future options. Increasing Possibility of BMJ accelerating development of daclatasvir/simeprevir IFN-free combination..... For more detail, please read our report released on 27th August 2012 on MVIR titled “Simeprevir in the HCV Race - Value Un-Appreciated”

I would like to order

Product name: Medivir AB - "Simeprevir in the HCV Race - Value Un-Appreciated"

Product link: <https://marketpublishers.com/r/MC0A4084F7EEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MC0A4084F7EEN.html>